Caixin Deep Dive: How AstraZeneca’s China Fraud Was About More Than Greed

The British pharmaceutical giant falsified patient test results to secure insurance coverage for its cancer drug in an effort to boost sales, but the alleged misconduct ended up benefiting some patients. Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin story:  Cover Story: How AstraZeneca’s China Fraud Was About More Than Greed Subscribe now to unlock all coverage from Caixin Global and The Wall Street Journal for just $200 a year, enjoying a 66% discount. Group discounts are available — contact us for a customized plan.